Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2018

View Archived Issues

Cellenkos manufacturing facility is successfully registered as GMP compliant with the FDA

Acesion Pharma cleared to conduct phase I study of AP-30663

Janssen submits MAA to EMA for apalutamide for nonmetastatic CRPC

Phase II trials of BI-409306 in Alzheimer's disease do not meet efficacy endpoints

Novo Nordisk's Ozempic approved in E.U.

Boehringer Ingelheim initiates phase I study of BI-1291583

Aravive studies AVB-S6-500 in healthy volunteers

Lundbeck updates progress of fourth quarter 2017

Tychan initiates phase Ia trial of first-in-class Zika antibody tyzivumab

Puma presents clinical data on neratinib in patients with HER2/3 mutant cancers

Phase III quality of life data reported for turoctocog alfa pegol in hemophilia A

Kissei presents novel CGRP antagonists

Retrophin divulges new pantetheine derivatives for neurodegeneration

New phase I/II trial evaluates lentiviral gene transfer for SCID-X1

Achaogen discloses novel ACC inhibitors for bacterial infections

Novel USP19 inhibitors presented by Almac Discovery

Toray Industries identifies MALT1 inhibitors

Roivant and Poxel sign development and license agreement for imeglimin

Seattle Genetics and Pieris Pharmaceuticals enter immune-oncology collaboration

Scholar Rock's SRK-015 antibody inhibits muscle wasting by binding myostatin precursors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...